SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Chemours Co. – ‘8-K’ for 3/1/21

On:  Tuesday, 3/2/21, at 5:07pm ET   ·   For:  3/1/21   ·   Accession #:  1564590-21-10323   ·   File #:  1-36794

Previous ‘8-K’:  ‘8-K’ on / for 2/11/21   ·   Next:  ‘8-K’ on 3/10/21 for 3/5/21   ·   Latest:  ‘8-K’ on 3/28/24 for 3/27/24   ·   3 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/02/21  Chemours Co.                      8-K:5,9     3/01/21   11:320K                                   ActiveDisclosure/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     32K 
 2: EX-10.1     Material Contract                                   HTML     65K 
 7: R1          Document And Entity Information                     HTML     46K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 6: XML         XBRL Instance -- cc-8k_20210301_htm                  XML     14K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- cc-20210301_lab                       XML     56K 
 5: EX-101.PRE  XBRL Presentations -- cc-20210301_pre                XML     34K 
 3: EX-101.SCH  XBRL Schema -- cc-20210301                           XSD     18K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
11: ZIP         XBRL Zipped Folder -- 0001564590-21-010323-xbrl      Zip     32K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C:   C:   C:   C: 
 i false  i 0001627223 0001627223 2021-03-01 2021-03-01

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM  i 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 i March 1, 2021

Date of Report (Date of Earliest Event Reported)

 i The Chemours Company

(Exact Name of Registrant as Specified in Its Charter)

 

 i  Delaware

 

 i 001-36794

 

 i 46-4845564

(State or Other Jurisdiction

 

(Commission

 

(I.R.S. Employer

Of Incorporation)

 

File Number)

 

Identification No.)

 

 i 1007 Market Street

 i Wilmington,  i Delaware  i 19801

(Address of principal executive offices)

 

Registrant’s telephone number, including area code:  i (302)  i 773-1000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 i 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 i 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 i 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Exchange on Which Registered

 i Common Stock ($0.01 par value)

 

 i CC

 

 i New York Stock Exchange

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

 i 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 


 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 1, 2021, The Chemours Company (the “Company”) entered into a separation agreement and release (the “Agreement”) with E. Bryan Snell, who served as the Company’s President – Titanium Technologies. Mr. Snell will retire from the Company on July 2, 2021, following the completion of a transition period. As previously disclosed, effective March 1, 2021, Edwin (Ed) Sparks becomes President Titanium Technologies.

 

As a continuing employee, Mr. Snell will receive salary, a prorated annual incentive program (AIP) award, and long-term incentive program grants commensurate with his prior role as President – Titanium Technologies for the period through July 2, 2021. Mr. Snell will also receive an additional one-time grant of stock options with a grant date fair value of $290,000 in recognition of his leadership in the development and execution of the multi-year Ti-PureTM Value Stabilization strategy within the Titanium Technologies segment and for his effective transition of the segment President role to his successor. Upon his separation from the Company, Mr. Snell will receive benefits consistent with the Company’s severance plans and policies as disclosed in the Company’s Proxy Statement for its 2020 annual meeting of stockholders, dated March 13, 2020.

 

In addition, pursuant to the Agreement, Mr. Snell will be compensated up to $110,000 for consulting services through December 31, 2021. In connection with ongoing non-competition obligations, Mr. Snell will be entitled to cash payments totaling $600,000. Mr. Snell will also have ongoing confidentiality and non-solicitation obligations under the Agreement.

 

Item 9.01.Financial Statements and Exhibits.

 

(d)Exhibits.

 

10.1

Separation Agreement and Release between E. Bryan Snell and the Company.

104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

THE CHEMOURS COMPANY

 

By:

 

/s/ Sameer Ralhan

 

 

Sameer Ralhan

 

 

Senior Vice President and Chief

 

 

Financial Officer

 

Date:

 

March 2, 2021

 

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
12/31/2110-K,  4,  SD
7/2/214
Filed on:3/2/21
For Period end:3/1/213,  4
3/13/204,  DEF 14A,  DEFA14A,  UPLOAD
 List all Filings 


3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/27/24  Chemours Co.                      10-K       12/31/23  200:50M                                    Donnelley … Solutions/FA
 2/10/23  Chemours Co.                      10-K       12/31/22  185:39M                                    Donnelley … Solutions/FA
 2/11/22  Chemours Co.                      10-K       12/31/21  185:36M                                    ActiveDisclosure/FA
Top
Filing Submission 0001564590-21-010323   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 3:52:07.1am ET